Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036920 | 0.84 | SMN1; SMN2 (0.62) | CHRM1CHRM2CHRM4CHRM5DRD2 | |
| SCHEMBL5337712 | 0.81 | CHRM1 (0.51) | CHRM1CHRM2CHRM4CHRM5DRD2 | |
| SCHEMBL13988119 | 0.81 | SMN1; SMN2 (0.57) | CHRM1CHRM2CHRM4CHRM5DRD2 | |
| SCHEMBL13472647 | 0.80 | EPHX1 (0.47) | CHRM4CHRM5CHRM3ADRA1BSMN1; SMN2 | |
| SCHEMBL8258898 | 0.80 | TSHR (0.47) | SMN1; SMN2HTR4ACHETSHRGNAO1 | |
| SCHEMBL15318157 | 0.79 | SMN1; SMN2 (0.56) | CHRM1CHRM2CHRM4CHRM5DRD2 | |
| SCHEMBL11570934 | 0.79 | TSHR (0.58) | HTR1AADRA2ASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL29252574 | 0.78 | CHRM1 (0.50) | CHRM1CHRM2CHRM4CHRM5DRD2 | |
| SCHEMBL28048043 | 0.78 | SMN1; SMN2 (0.58) | CHRM2ADRA1AHTR1AADRA2AHRH1 | |
| SCHEMBL420355 | 0.77 | HRH1 (0.47) | CHRM1CHRM2CHRM4CHRM5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | claimed |
| CN-1439002-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2003-08-27 | — | — | CN | claimed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| CN-101016296-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| CN-1814596-A | Muscarinic agonists | ARCADIA PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1249051-C | Muscarinic agonists | ACADIA PHARM INC (US) | 2006-04-05 | — | — | CN | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM2 2/4885CHRM4 4/4885 |
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM2 2/4885CHRM4 4/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.